

GLOBAL MARKETS FOR INFECTIOUS DISEASE TREATMENTS



PHM061B
May 2013

Peggy Lehr
Project Analyst

ISBN: 1-56965-326-7

bcc | Research
Market Forecasting

BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481
866-285-7215, 781-489-7301
www.bccresearch.com
Custom Reports:
carol.laverty@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY GOALS AND OBJECTIVES	2
REASONS FOR DOING THE STUDY	2
SCOPE OF REPORT	2
INTENDED AUDIENCE	3
METHODOLOGIES AND INFORMATION SOURCES	3
ANALYST CREDENTIALS	3
RELATED BCC REPORTS	3
BCC ON-LINE SERVICES	4
DISCLAIMER	4
CHAPTER 2 SUMMARY	6
<i>SUMMARY TABLE PROJECTED MARKET FOR INFECTIOUS DISEASES DIAGNOSTIC, VACCINE AND PHARMACEUTICAL PRODUCTS BY TYPE, THROUGH 2017 (\$ MILLIONS)</i>	7
<i>SUMMARY FIGURE PERCENTAGE OF MARKET SHARE FOR INFECTIOUS DISEASE DIAGNOSTIC, VACCINE AND PHARMACEUTICAL PRODUCTS BY GEOGRAPHIC REGION, 2012 AND 2017 (%)</i>	8
CHAPTER 3 OVERVIEW OF THE GLOBAL STATE OF INFECTIOUS DISEASE DIAGNOSIS, VACCINES, AND TREATMENT	10
TOP GLOBAL CAUSES OF DEATH	10
<i>TABLE 1 GLOBAL PERCENTAGE OF DEATHS BY TYPE OF DISEASE, CAUSE, INCOME LEVEL (%)</i>	11
MAJOR INFECTIOUS DISEASES	11
<i>TABLE 2 SELECTED MAJOR INFECTIOUS DISEASES, WORLDWIDE, 2011 (NUMBER OF CASES, TREATMENT OPTIONS)</i>	11
HISTORICAL IMPACT OF INFECTIOUS DISEASES	12
LEADING CAUSES OF GLOBAL DEATHS	13
Transmission of Infectious Diseases	13
LINKING INFECTIOUS DISEASE TO CANCER	13
TREATMENTS FOR INFECTIOUS DISEASES	13
PREVENTION	13
VACCINATION	14
<i>FIGURE 1 VACCINE-PREVENTABLE DEATHS IN CHILDREN UNDER FIVE YEARS OF AGE, 2008 (THOUSANDS)</i>	14
<i>TABLE 3 VACCINE-PREVENTABLE DISEASE DEATHS IN CHILDREN UNDER 5 YEARS OF AGE BY REGION, 2008 (000)</i>	15
GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET	15
TYPES OF DIAGNOSTIC TESTING	15
FLUORESCENT IMMUNOASSAY (FIA)	16
Direct Fluorescent Antibody Testing (FA)	16
Indirect Fluorescent Antibody Testing (IFA)	16
Chemiluminescent Microparticle Immunoassay (CIA)	16
ENZYLE IMMUNOASSAY (EIA)	16
Basic EIA	17
Enzyme-Linked Immunosorbent Assay (ELISA)	17
GENE PROBE ANALYSIS	17

TOPIC	PAGE NO.
Polymerase Chain Reaction Amplification (PCR)	18
Nucleic Acid Amplification Test (NAT)	18
Transcription-Mediated Amplification (TMA)	18
Nucleic Acid Sequence-Based Amplification (NASBA)	19
GLOBAL MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS	19
<i>TABLE 4 PROJECTED GLOBAL MARKET FOR HUMAN INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS, THROUGH 2017 (\$ MILLIONS)</i>	19
GLOBAL INFECTIOUS DISEASE VACCINE MARKET	19
<i>TABLE 5 PROJECTED GLOBAL MARKET FOR HUMAN INFECTIOUS DISEASE VACCINE PRODUCTS, THROUGH 2017 (\$ MILLIONS)</i>	20
THE GLOBAL INFECTIOUS DISEASE PHARMACEUTICAL MARKET	20
<i>TABLE 6 PROJECTED GLOBAL MARKET FOR HUMAN INFECTIOUS DISEASE PHARMACEUTICAL PRODUCTS, THROUGH 2017 (\$ MILLIONS)</i>	20
PROJECTIONS FOR GLOBAL INFECTIOUS DISEASE PRODUCTS BY TYPE AND DISEASE	21
<i>TABLE 7 PROJECTED GLOBAL MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC, VACCINE AND TREATMENT PRODUCTS, THROUGH 2017 (\$ MILLIONS)</i>	21
VACCINE OPPORTUNITIES	22
CHILDHOOD DISEASES	22
GLOBAL HUMANITARIAN AGENCIES	22
PHARMACEUTICAL OPPORTUNITIES	23
THE EMERGENCE OF GENE THERAPY	23
MERGERS AND ACQUISITIONS	24
<i>TABLE 8 SELECTED MERGERS AND ACQUISITIONS, 2008-2013 (\$ MILLIONS)</i>	24
CHAPTER 4 VACCINES-THE PRESENT AND THE FUTURE	26
MARKET FOR HUMAN INFECTIOUS DISEASE VACCINES	26
<i>TABLE 9 PROJECTED GLOBAL MARKET FOR INFECTIOUS DISEASE VACCINES, THROUGH 2017 (\$ MILLIONS)</i>	26
TYPES OF VACCINES	27
LIVE ATTENUATED VACCINE	27
INACTIVATED VACCINE	27
Acellular/Subunit Vaccines	27
IMMUNITY	27
INNATE IMMUNITY	28
ACQUIRED IMMUNITY	28
The Activity of T Cells	28
Acquired Immunity-Cell-Mediated Response	29
LASTING IMMUNITY	29
VIRAL DISEASES PREVENTED BY VACCINE	29
<i>TABLE 10 VIRUSES, THE DISEASES THEY CAUSE, AND AVAILABLE VACCINES</i>	29
BACTERIAL DISEASES PREVENTED BY VACCINE	30
<i>TABLE 11 BACTERIA, THE DISEASES THEY CAUSE, AND AVAILABLE VACCINES</i>	30
VACCINATION SCHEDULES FOR CHILDREN	30
<i>TABLE 12 IMMUNIZATION SCHEDULE FOR CHILDREN FROM BIRTH TO 6 MONTHS</i>	31
<i>TABLE 13 IMMUNIZATION SCHEDULE FOR CHILDREN FROM 12 MONTHS TO 4 TO 6 YEARS</i>	31
<i>TABLE 14 IMMUNIZATION SCHEDULE FOR CHILDREN AND ADOLESCENTS FROM 7 TO 18</i>	32

TOPIC	PAGE NO.
CONCERNS REGARDING VACCINATION IN CHILDHOOD	32
NUMBER OF INOCULATIONS	32
RECOGNIZING IMMUNE RESPONSE	32
IMMUNIZATION AND WEAKENED OR ALTERED IMMUNE SYSTEMS	33
VACCINE PRODUCTION	33
<i>FIGURE 2 VACCINE MANUFACTURING PROCESS</i>	33
VACCINE MANUFACTURERS	34
TOP- SELLING VACCINES OF 2011	35
<i>TABLE 15 TOP-SELLING INFECTIOUS DISEASE VACCINES WITH APPLICATION, MANUFACTURER AND REVENUE, 2011</i>	35
REGIONAL ANALYSIS	35
<i>TABLE 16 PROJECTED REGIONAL MARKETS FOR VACCINES, THROUGH 2017 (\$ MILLIONS)</i>	35
<i>FIGURE 3 PERCENTAGE OF MARKET SHARE FOR VACCINES BY REGION, 2012 AND 2017</i>	36
THE AMERICAS	37
<i>TABLE 17 PROJECTED AMERICAS MARKET FOR INFECTIOUS DISEASE VACCINES BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	37
<i>TABLE 18 PROJECTED AMERICAS MARKET FOR INFECTIOUS DISEASE VACCINES BY DISEASE, THROUGH 2017 (\$ MILLIONS)</i>	38
EMRA	38
<i>TABLE 19 PROJECTED EMRA MARKET FOR HUMAN INFECTIOUS DISEASE VACCINES, BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	38
<i>TABLE 20 PROJECTED EMRA MARKET FOR HUMAN INFECTIOUS DISEASE VACCINES, BY DISEASE, THROUGH 2017 (\$ MILLIONS)</i>	39
ASIA	39
<i>TABLE 21 PROJECTED ASIAN MARKET FOR HUMAN INFECTIOUS DISEASE VACCINES, BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	39
<i>TABLE 22 PROJECTED ASIAN MARKET FOR HUMAN INFECTIOUS DISEASE VACCINES, BY DISEASE, THROUGH 2017 (\$ MILLIONS)</i>	40
TRENDS IN VACCINE DEVELOPMENT	40
COMBINATION VACCINES	40
INHALED OR INTRANASAL VACCINE ADMINISTRATION	40
CHAPTER 5 VIRAL INFECTIOUS DISEASES	43
GLOBAL MARKET FOR VIRAL INFECTIOUS DISEASE DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS	43
<i>TABLE 23 PROJECTED GLOBAL MARKET FOR VIRAL INFECTIOUS DISEASE DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2017 (\$ MILLIONS)</i>	43
HEPATITIS B AND C	43
<i>TABLE 24 PROJECTED GLOBAL MARKET FOR HEPATITIS DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2017 (\$ MILLIONS)</i>	44
RISK FACTORS	44
TREATMENTS	44
HERPES SIMPLEX VIRUS	45
<i>TABLE 25 PROJECTED GLOBAL MARKET FOR HSV DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2017 (\$ MILLIONS)</i>	45
INCIDENCE	45
DIAGNOSIS	46

TOPIC	PAGE NO.
<i>TABLE 26 CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF GENITAL HERPES BY BRAND NAME, TYPE AND MANUFACTURER, 2012</i>	46
TREATMENT	47
<i>TABLE 27 MEDICATIONS USED TO TREAT HSV BY BRAND NAME, GENERIC NAME AND MANUFACTURER</i>	47
HEPATITIS B AND C	48
<i>TABLE 28 PROJECTED GLOBAL MARKET FOR HEPATITIS B AND C DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2017 (\$ MILLIONS)</i>	48
DIAGNOSIS	48
<i>TABLE 29 HEPATITIS B AND C DIAGNOSTIC PRODUCT MARKET SHARE BY TYPE OF TEST AND REVENUES, 2011 (\$ MILLIONS/%)</i>	48
<i>TABLE 30 CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF HEPATITIS B AND C BY BRAND NAME AND MANUFACTURER, 2012</i>	49
Automated Infectious Disease Testing for Hepatitis	50
TREATMENT MARKET	50
<i>TABLE 31 HEPATITIS B AND C TREATMENT MANUFACTURER MARKET STANDING, BY REVENUES, 2011 (\$ MILLIONS)</i>	51
<i>FIGURE 4 TOP PHARMACEUTICAL MANUFACTURERS IN THE HEPATITIS MARKET AND THEIR MARKET SHARE, 2011 (%)</i>	51
<i>TABLE 32 MEDICATIONS FOR THE TREATMENT OF HEPATITIS B AND C, 2012</i>	52
HIV/AIDS	52
<i>TABLE 33 PROJECTED GLOBAL MARKET FOR HIV DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2017 (\$ MILLIONS)</i>	53
RISK FACTORS	53
INCIDENCE/MORTALITY	54
HAART TREATMENT	54
HAART Failure	55
Mega-HAART	55
HIV TREATMENT FOR INFANTS	55
HUMAN PAPILLOMAVIRUS	55
HPV AND CANCER	55
INCIDENCE	56
SYMPTOMS	56
DIAGNOSIS	56
<i>TABLE 34 CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF HPV BY BRAND NAME, TYPE AND MANUFACTURER, 2012</i>	57
TREATMENT	57
<i>TABLE 35 MEDICATIONS USED TO TREAT HPV BY BRAND NAME, GENERIC NAME, AND MANUFACTURER</i>	57
INFLUENZA A AND B	57
VACCINE	58
TREATMENT	58
MEASLES	58
PNEUMONIA	58
BACTERIAL PNEUMONIA	58
Vaccine	59
Treatment	59
VIRAL PNEUMONIA	59
Treatment	59

TOPIC	PAGE NO.
ROTAVIRUS	59
DEHYDRATION	60
ZINC	60
RSV	60
SYMPTOMS	60
DIAGNOSTIC PRODUCTS	61
<i>TABLE 36 RSV DIAGNOSTIC PRODUCTS BY BRAND NAME, MANUFACTURER AND TYPE 2012</i>	61
VIRAL DIAGNOSTIC PRODUCTS	61
<i>TABLE 37 PROJECTED GLOBAL MARKET FOR VIRAL INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS, THROUGH 2017 (\$ MILLIONS)</i>	62
VIRAL PHARMACEUTICAL PRODUCTS	62
<i>TABLE 38 PROJECTED GLOBAL MARKET FOR VIRAL INFECTIOUS DISEASE PHARMACEUTICAL PRODUCTS, THROUGH 2017 (\$ MILLIONS)</i>	62
REGIONAL ANALYSIS	63
<i>TABLE 39 PROJECTED GLOBAL MARKET FOR VIRAL INFECTIOUS DISEASE DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	63
<i>FIGURE 5 PERCENTAGE OF THE GLOBAL VIRAL DIAGNOSTIC AND PHARMACEUTICAL MARKETS BY REGIONS, 2012 AND 2017 (%)</i>	63
<i>TABLE 40 PROJECTED MARKET FOR VIRAL DIAGNOSTIC PRODUCTS BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	64
<i>TABLE 41 PROJECTED MARKET FOR VIRAL PHARMACEUTICAL PRODUCTS BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	65
AMERICAS	65
Hepatitis B in the U.S.	65
Hepatitis C in the U.S.	66
Hepatitis in Canada	66
Market for Viral Infectious Disease Products in the Americas	66
<i>TABLE 42 PROJECTED AMERICAS MARKET FOR VIRAL INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	66
<i>TABLE 43 PROJECTED AMERICAS MARKET FOR VIRAL INFECTIOUS DISEASE PHARMACEUTICAL PRODUCTS BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	67
Americas Diagnostic and Pharmaceutical Products Market, by Disease	67
<i>TABLE 44 PROJECTED AMERICAS MARKET FOR VIRAL INFECTIOUS DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, BY DISEASE, THROUGH 2017 (\$ MILLIONS)</i>	67
EMRA	67
Hepatitis B, C in EMRA	67
Hepatitis in Africa	68
Hepatitis in Russia, Eurasia	68
Market for Viral Infectious Disease Diagnostic and Pharmaceutical Products	68
<i>TABLE 45 PROJECTED EMRA MARKET FOR VIRAL INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	68
<i>TABLE 46 PROJECTED EMRA MARKET FOR VIRAL INFECTIOUS DISEASE PHARMACEUTICAL PRODUCTS BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	69
EMRA Market for Infectious Disease Diagnostic and Pharmaceutical Products, by Disease	69
<i>TABLE 47 PROJECTED EMRA MARKET FOR VIRAL INFECTIOUS DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, BY DISEASE, THROUGH 2017 (\$ MILLIONS)</i>	70

TOPIC	PAGE NO.
ASIA	70
Hepatitis in Asian Region	70
Hepatitis in Japan	70
Hepatitis in China	70
Hepatitis in India	71
<i>TABLE 48 PROJECTED ASIAN MARKET FOR VIRAL INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	71
<i>TABLE 49 PROJECTED ASIAN MARKET FOR VIRAL INFECTIOUS DISEASE PHARMACEUTICAL PRODUCTS BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	71
<i>TABLE 50 PROJECTED ASIAN MARKET FOR VIRAL INFECTIOUS DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, BY DISEASE, THROUGH 2017 (\$ MILLIONS)</i>	72
CHAPTER 6 BACTERIAL INFECTIOUS DISEASES AND THE SPECTER OF ANTIBIOTIC RESISTANCE	74
NEGLECTED TROPICAL BACTERIAL INFECTIOUS DISEASES	74
<i>TABLE 51 NEGLECTED TROPICAL BACTERIAL INFECTIOUS DISEASES</i>	74
MARKET FOR BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS	74
<i>TABLE 52 PROJECTED GLOBAL MARKET FOR BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC AND TREATMENT PRODUCTS, THROUGH 2017 (\$ MILLIONS)</i>	75
MARKET FOR BACTERIAL INFECTIOUS DISEASE DIAGNOSTICS	75
<i>TABLE 53 PROJECTED GLOBAL MARKET FOR BACTERIAL INFECTIOUS DISEASES DIAGNOSTICS, THROUGH 2017 (\$ MILLIONS)</i>	75
MARKET FOR BACTERIAL INFECTIOUS DISEASES PHARMACEUTICALS	76
<i>TABLE 54 PROJECTED GLOBAL MARKET FOR BACTERIAL INFECTIOUS DISEASES PHARMACEUTICALS, THROUGH 2017 (\$ MILLIONS)</i>	76
NOTABLE BACTERIAL DISEASES	76
CORYNEBACTERIUM DIPHTHERIAE, CLOSTRIDIUM TETANI, BORDETELLA PERTUSSIS	76
Diphtheria	76
Tetanus	77
Pertussis	77
MENINGITIS	77
MYCOBACTERIUM TUBERCULOSIS (TB)	78
<i>TABLE 55 PROJECTED GLOBAL MARKET FOR TB DIAGNOSTIC AND PHARMACEUTICAL TREATMENTS, THROUGH 2017 (\$ MILLIONS)</i>	78
EPIDEMIOLOGY OF TB	78
GEOGRAPHIC PREVALENCE	79
<i>TABLE 56 PROJECTED MARKET FOR TB DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	79
FINANCING CONTROL EFFORTS	80
ANTIBIOTIC DEVELOPMENT	80
<i>TABLE 57 HISTORY OF ANTIBIOTIC DISCOVERY AND APPROVAL</i>	80
<i>TABLE 58 ANTIBIOTIC CLASSES AND THEIR MODE OF ACTION</i>	81
ANTIBIOTIC RESISTANCE	81
MECHANISMS OF RESISTANCE	82
METHODS OF RESISTANCE	83
Beta-Lactamase Production	83
Importing Resistance from Other Organisms	83
Examples of Antibiotic-Resistant Bacteria	84

TOPIC	PAGE NO.
Alteration of Binding Sites to Circumvent Anti-Infective Effectiveness	84
Antibiotic Discharge	84
PRIMARY REASONS FOR ANTIBIOTIC RESISTANCE	85
FAILURE TO FINISH ANTIBIOTIC COURSES	85
ANTIBIOTIC OVERUSE	85
AGRICULTURAL PRACTICES	85
<i>TABLE 59 ANTIBIOTICS APPROVED FOR USE IN FOOD-PRODUCING ANIMALS IN 2009, BY DRUG CLASS, POUNDS USED, AND PERCENTAGE OF TOTAL (POUNDS/%)</i>	86
PATIENT PRESSURE	86
INTERNATIONAL SURVEILLANCE OF ANTIBIOTIC-RESISTANT ORGANISMS	87
RESISTANCE BY CLASS OF ANTIBIOTIC	87
<i>TABLE 60 ANTIBIOTIC-RESISTANT ORGANISMS AND DRUG CLASSES AFFECTED</i>	87
INCIDENCES OF ANTIBIOTIC RESISTANCE	87
ANTIBIOTIC RESISTANCE IN EUROPE	87
ANTIBIOTIC RESISTANCE IN THE U.S.	88
MAJOR ANTIBIOTIC-RESISTANT ORGANISMS	88
VANCOMYCIN-RESISTANT ENTEROCOCCUS (VRE)	88
METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA)	88
CLOSTRIDIUM DIFFICILE (C. DIFFICILE)	89
REGIONAL ANALYSIS	89
<i>TABLE 61 PROJECTED GLOBAL MARKET FOR BACTERIAL DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	89
<i>FIGURE 6 MARKET SHARE OF BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS BY REGION, 2012 AND 2017 (%)</i>	89
THE AMERICAS	90
<i>TABLE 62 PROJECTED AMERICAS MARKET FOR BACTERIAL DIAGNOSTIC AND PHARMACEUTICAL TREATMENTS, THROUGH 2017 (\$ MILLIONS)</i>	91
Bacterial Infection Diagnostic Product Market in the Americas	91
<i>TABLE 63 BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC PRODUCT MARKET IN THE AMERICAS BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	91
Bacterial Infection Pharmaceutical Market in the Americas	91
<i>TABLE 64 BACTERIAL INFECTION PHARMACEUTICAL PRODUCT MARKET IN THE AMERICAS, BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	91
Americas Bacterial Infectious Diseases Diagnostic and Pharmaceutical Market, by Disease	92
<i>TABLE 65 PROJECTED AMERICAS MARKET FOR BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, BY DISEASE, THROUGH 2017 (\$ MILLIONS)</i>	92
EMRA	93
<i>TABLE 66 PROJECTED EMRA MARKET FOR BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2017 (\$ MILLIONS)</i>	93
Bacterial Infectious Diseases Diagnostic Market in EMRA	93
<i>TABLE 67 BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC PRODUCT MARKET IN EMRA BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	94
Bacterial Infectious Diseases Pharmaceutical Product Market in EMRA	94
<i>TABLE 68 BACTERIAL INFECTIOUS DISEASES PHARMACEUTICAL PRODUCT MARKET IN EMRA BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	94
EMRA Bacterial Infectious Diseases Diagnostic and Pharmaceutical Market, by Disease	94

TOPIC	PAGE NO.
<i>TABLE 69 PROJECTED EMRA MARKET FOR BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS BY DISEASE, THROUGH 2017 (\$ MILLIONS)</i>	94
ASIA	95
<i>TABLE 70 PROJECTED ASIA MARKET FOR BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC AND PHARMACEUTICAL TREATMENTS, THROUGH 2017 (\$ MILLIONS)</i>	96
Bacterial Infectious Diseases Diagnostic Product Market in Asia	96
<i>TABLE 71 BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC PRODUCT MARKET IN ASIA BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	96
Bacterial Infectious Diseases Pharmaceutical Product Market in Asia	97
<i>TABLE 72 BACTERIAL INFECTIOUS DISEASES PHARMACEUTICAL PRODUCT MARKET IN ASIA, BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	97
Asian Bacterial Infectious Diseases Diagnostic and Pharmaceutical Market, by Disease	97
<i>TABLE 73 PROJECTED ASIAN MARKET FOR BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, BY DISEASE, THROUGH 2017 (\$ MILLIONS)</i>	97
CHAPTER 7 PARASITIC INFECTIOUS DISEASES	99
NEGLECTED TROPICAL PARASITIC INFECTIOUS DISEASES	99
<i>TABLE 74 NEGLECTED TROPICAL PARASITIC INFECTIOUS DISEASES</i>	99
CLIMATE CHANGE AND VECTOR-BORNE DISEASES	99
MALARIA	100
INCIDENCES OF MALARIA	100
<i>TABLE 75 ESTIMATED 2010 GLOBAL MALARIA CASES AND ESTIMATED DEATHS, RATE OF DECREASE OF MALARIA DEATHS SINCE 2000, BY REGION*</i>	101
CAUSES OF MALARIA	101
SYMPTOMS OF MALARIA	101
GLOBAL MARKET FOR MALARIAL PREVENTION, DIAGNOSTIC AND PHARMACEUTICAL TREATMENTS	101
<i>TABLE 76 PROJECTED GLOBAL MARKET FOR MALARIAL PREVENTION, DIAGNOSTIC AND PHARMACEUTICAL TREATMENTS, THROUGH 2017 (\$ MILLIONS)</i>	102
INTERVENTIONAL TECHNIQUES TO MINIMIZE EXPOSURE TO MALARIAL VECTORS	102
<i>TABLE 77 PROJECTED GLOBAL MARKET FOR INSECTICIDE-TREATED NETS, THROUGH 2017 (\$ MILLIONS)</i>	102
DIAGNOSIS OF MALARIA	103
<i>TABLE 78 PROJECTED GLOBAL MARKET FOR MALARIAL DIAGNOSTIC PRODUCTS, THROUGH 2017 (\$ MILLIONS)</i>	103
TREATMENT OF MALARIA	103
<i>TABLE 79 CURRENT PHARMACEUTICALS FOR TREATMENT OF MALARIA, WITH TREATMENT AND MANUFACTURER, 2012</i>	104
<i>TABLE 80 PROJECTED GLOBAL MARKET FOR MALARIAL DRUG TREATMENTS, THROUGH 2017 (\$ MILLIONS)</i>	104
REGIONAL ANALYSIS	104
REGIONAL ANALYSIS	105
<i>TABLE 81 PROJECTED GLOBAL MARKET FORMAL ARIAL PREVENTION, DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	105
<i>FIGURE 7 GLOBAL MARKET FOR MALARIAL TREATMENTS BY REGION 2012 AND 2017 (%)</i>	105
THE AMERICAS	106

TOPIC	PAGE NO.
<i>TABLE 82 PROJECTED AMERICAS MARKET FOR MALARIAL PREVENTION, DIAGNOSTIC AND PHARMACEUTICAL TREATMENTS, THROUGH 2017 (\$ MILLIONS)</i>	107
Malarial Prevention Product Market in the Americas	107
<i>TABLE 83 MALARIAL PREVENTION PRODUCT MARKET IN THE AMERICAS BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	107
Malarial Diagnostic Product Market in the Americas	107
<i>TABLE 84 MALARIAL DIAGNOSTIC PRODUCT MARKET IN THE AMERICAS BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	108
Malarial Pharmaceutical Market in the Americas	108
<i>TABLE 85 MALARIAL PHARMACEUTICAL PRODUCT MARKET IN THE AMERICAS BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	108
EMRA	108
<i>TABLE 86 PROJECTED EMRA MARKET FOR MALARIAL PREVENTIVE, DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2017 (\$ MILLIONS)</i>	109
Malarial Prevention Market in the EMRA	109
<i>TABLE 87 MALARIAL PREVENTIVE PRODUCT MARKET IN EMRA, BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	109
Malarial Diagnostic Product Market in EMRA	109
<i>TABLE 88 MALARIAL DIAGNOSTIC PRODUCT MARKET IN EMRA, BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	110
Malarial Pharmaceutical Product Market in the EMRA	110
<i>TABLE 89 MALARIAL PHARMACEUTICAL PRODUCT MARKET IN THE EMRA, BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	110
ASIA	110
<i>TABLE 90 PROJECTED ASIA MARKET FOR MALARIAL PREVENTION, DIAGNOSTIC, AND PHARMACEUTICAL TREATMENTS, THROUGH 2017 (\$ MILLIONS)</i>	111
<i>TABLE 91 MALARIAL PREVENTION PRODUCT MARKET IN ASIA BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	111
<i>TABLE 92 MALARIAL DIAGNOSTIC PRODUCT MARKET IN ASIA BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	112
<i>TABLE 93 MALARIAL PHARMACEUTICAL PRODUCT MARKET IN ASIA BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	112
<i>TABLE 94 CURRENT ANT PARASITIC PHARMACEUTICALS WITH TRADENAME, GENERIC NAME, MANUFACTURER, AND AREA OF TREATMENT, 2012</i>	113
MARKET FOR ANTIPARASITIC PHARMACEUTICALS	113
CHAPTER 8 EMERGING TECHNOLOGY AND PHARMACEUTICALS	115
HEPATITIS C	115
POLYMERASE	115
Vertex Pharmaceuticals	115
NS5B	115
Roche	115
Boehringer Ingelheim	115
INFLUENZA	115
VAXINNATE	116
HSV	116
MALARIA	117
VACCINE	117
PHARMACEUTICALS	117
DIAGNOSTIC TESTING	117

TOPIC	PAGE NO.
ANTIBIOTIC RESISTANCE	118
GALAPAGOS NV	118
TRIOUS THERAPEUTICS	118
CRESTONE PHARMA	119
BASILEA PHARMACEUTICA	119
POLYPHOR	119
REMPEX PHARMA	119
PHARMACEUTICAL TREATMENT PRODUCT PIPELINE	120
<i>TABLE 95 INFECTIOUS DISEASES PHARMACEUTICAL PRODUCT PIPELINE, BY DISEASE, 2012</i>	120
CHAPTER 9 PATENT ANALYSIS	128
PHARMACEUTICAL PATENTS, BY PATENT NUMBER, DISEASE, COMPANY, DESCRIPTION AND APPROVAL DATE	128
<i>TABLE 96 INFECTIOUS DISEASES PHARMACEUTICAL AND VACCINE PATENTS, BY PATENT NUMBER, DISEASE, COMPANY, PRODUCT DESCRIPTION AND APPROVAL DATE, FEBRUARY 2006 TO FEBRUARY 2013</i>	129
DIAGNOSTIC PATENTS ISSUED, BY COMPANY, APPROVAL DATE, AND DISEASE	141
<i>TABLE 97 INFECTIOUS DISEASES DIAGNOSTIC PATENTS, BY PATENT NUMBER, DISEASE, COMPANY, PRODUCT DESCRIPTION, AND APPROVAL DATE, MARCH 2005-DECEMBER 2012</i>	142
PATENTS ISSUED BY COMPANY	142
<i>TABLE 98 INFECTIOUS DISEASES PHARMACEUTICAL, VACCINE, AND DIAGNOSTIC PRODUCT PATENTS BY COMPANY, MARCH 2005-FEBRUARY 2013</i>	143
PATENTS ISSUED BY COUNTRY	144
<i>TABLE 99 INFECTIOUS DISEASE PRODUCT DIAGNOSIS, VACCINE AND TREATMENT PATENTS BY COUNTRY, JANUARY 2005 TO FEBRUARY 2013 (NUMBER/%)</i>	145
<i>FIGURE 8 NUMBER OF INFECTIOUS DISEASES PRODUCT DIAGNOSIS, VACCINE AND TREATMENT PATENTS BY COUNTRY, JANUARY 2005-FEBRUARY 2013 (%)</i>	146
INFECTIOUS DISEASES PATENTS ISSUED, BY DISEASE	146
<i>TABLE 100 PATENTS ISSUED FOR DIAGNOSIS, VACCINE AND TREATMENT OF INFECTIOUS DISEASES, BY DISEASE, MARCH 2005-FEBRUARY 2013 (NUMBER/%)</i>	146
<i>FIGURE 9 INFECTIOUS DISEASES DIAGNOSTIC, VACCINE AND PHARMACEUTICAL PATENTS BY DISEASE ISSUED BETWEEN MARCH 2005 AND DECEMBER 2012, (%)</i>	147
INFECTIOUS DISEASES PATENTS, BY YEAR	147
<i>TABLE 101 NUMBER OF INFECTIOUS DISEASES PATENTS FOR DIAGNOSTIC, VACCINE AND PHARMACEUTICAL PRODUCTS, BY DISEASE AND YEAR, 2005-2013</i>	148
CHAPTER 10 COMPANY PROFILES	150
ABBOTT LABORATORIES	150
BUSINESS OVERVIEW	150
PRODUCTS	150
<i>TABLE 102 ABBOTT PHARMACEUTICAL PRODUCTS</i>	150
DIAGNOSTIC PRODUCTS	151
<i>TABLE 103 ABBOTT DIAGNOSTIC PRODUCTS</i>	151
ALERE	151
BUSINESS OVERVIEW	151
PRODUCTS	152
<i>TABLE 104 ALERE DIAGNOSTIC PRODUCTS</i>	152
ALFA SCIENTIFIC DESIGNS	153

TOPIC	PAGE NO.
BUSINESS OVERVIEW	153
PRODUCTS	153
<i>TABLE 105 ALFA SCIENTIFIC DESIGNS DIAGNOSTIC PRODUCTS</i>	153
ATLAS LINK BIOTECH CO., LTD.	154
BUSINESS OVERVIEW	154
PRODUCTS	154
<i>TABLE 106 ATLAS LINK BIOTECH DIAGNOSTIC PRODUCTS</i>	154
ASTRA ZENECA	155
BUSINESS OVERVIEW	155
PRODUCTS	155
<i>TABLE 107 ASTRA ZENECA PHARMACEUTICAL PRODUCTS</i>	155
BAXTER HEALTHCARE	155
BUSINESS OVERVIEW	155
PRODUCTS	156
<i>TABLE 108 BAXTER PHARMACEUTICAL PRODUCTS</i>	156
BAYER AG	156
BUSINESS OVERVIEW	156
PRODUCTS	156
<i>TABLE 109 BAYER PHARMACEUTICAL PRODUCTS</i>	156
BECTON DICKINSON	157
BUSINESS OVERVIEW	157
PRODUCTS	157
<i>TABLE 110 BECTON DICKINSON DIAGNOSTIC PRODUCTS</i>	157
BIO-RAD LABORATORIES	157
BUSINESS OVERVIEW	157
PRODUCTS	158
<i>TABLE 111 BIORAD DIAGNOSTIC PRODUCTS</i>	158
BOEHRINGER INGELHEIM GMBH	158
BUSINESS OVERVIEW	158
PRODUCTS	159
<i>TABLE 112 BOEHRINGER INGELHEIM PHARMACEUTICAL PRODUCTS</i>	159
BRISTOL-MYERS SQUIBB COMPANY	159
BUSINESS OVERVIEW	159
PRODUCTS	159
<i>TABLE 113 BRISTOL-MYERS SQUIBB PHARMACEUTICAL PRODUCTS</i>	159
CEPHEID	160
BUSINESS OVERVIEW	160
PRODUCTS	160
<i>TABLE 114 CEPHEID DIAGNOSTIC PRODUCTS</i>	160
CRUCCELL NV	160
BUSINESS OVERVIEW	161
PRODUCTS	161
<i>TABLE 115 CRUCCELL VACCINE PRODUCTS</i>	161
CUBIST PHARMACEUTICALS	162
BUSINESS OVERVIEW	162
PRODUCTS	162
<i>TABLE 116 CUBIST PHARMACEUTICAL PRODUCT</i>	162

TOPIC	PAGE NO.
DIAGNOSTIC AUTOMATION/CORTEZ DIAGNOSTICS INC.	162
BUSINESS OVERVIEW	162
PRODUCTS	163
<i>TABLE 117 DIAGNOSTIC AUTOMATION/CORTEZ DIAGNOSTICS DIAGNOSTIC PRODUCTS</i>	163
DIASORIN	163
BUSINESS OVERVIEW	164
PRODUCTS	164
<i>TABLE 118 DIAGNOSTIC PRODUCTS</i>	164
ENANTA PHARMACEUTICALS	164
BUSINESS OVERVIEW	164
ENZO BIOCHEM	165
BUSINESS OVERVIEW	165
PRODUCTS	165
<i>TABLE 119 ENZO BIOCHEM DIAGNOSTIC PRODUCTS</i>	165
FIRST DIAGNOSTIC LLC	165
BUSINESS OVERVIEW	165
PRODUCTS	166
<i>TABLE 120 FIRST DIAGNOSTIC PRODUCTS</i>	166
GILEAD SCIENCES INC.	166
BUSINESS OVERVIEW	166
PRODUCTS	167
<i>TABLE 121 GILEAD SCIENCES PHARMACEUTICAL PRODUCTS</i>	167
GLAXOSMITHKLINE	167
BUSINESS OVERVIEW	167
PRODUCTS	168
<i>TABLE 122 GLAXOSMITHKLINE PHARMACEUTICAL/VACCINE PRODUCTS</i>	168
HOLOGIC GEN-PROBE INC.	169
BUSINESS OVERVIEW	169
PRODUCTS	169
<i>TABLE 123 HOLOGIC/GENPROBE DIAGNOSTIC PRODUCTS</i>	169
HOME ACCESS HEALTH INC.	169
BUSINESS OVERVIEW	170
PRODUCTS	170
<i>TABLE 124 HOME ACCESS DIAGNOSTIC PRODUCTS</i>	170
IDENIX PHARMACEUTICALS	170
BUSINESS OVERVIEW	170
IMMUNOSTICS	170
BUSINESS OVERVIEW	171
PRODUCTS	171
<i>TABLE 125 IMMUNOSTICS DIAGNOSTIC PRODUCTS</i>	171
IND DIAGNOSTIC INC.	171
BUSINESS OVERVIEW	171
PRODUCTS	172
<i>TABLE 126 IND DIAGNOSTIC PRODUCTS</i>	172
INVERNESS MEDICAL INNOVATIONS (SEE ALERE)	172
IPCA LABORATORIES	172
BUSINESS OVERVIEW	172

TOPIC	PAGE NO.
JANSSEN THERAPEUTICS (FORMERLY TIBOTEC THERAPEUTICS)	173
BUSINESS OVERVIEW	173
PRODUCTS	173
<i>TABLE 127 JANSSEN THERAPEUTICS PHARMACEUTICAL PRODUCTS</i>	173
MANGALAM DRUGS & ORGANICS LTD.	173
BUSINESS OVERVIEW	173
MEDMIRA INC	174
BUSINESS OVERVIEW	174
PRODUCTS	174
<i>TABLE 128 EDMIRA DIAGNOSTIC PRODUCTS</i>	174
MERCK & COMPANY INC.	174
BUSINESS OVERVIEW	174
PRODUCTS	175
<i>TABLE 129 MERCK VACCINE PRODUCTS</i>	175
<i>TABLE 130 MERCK PHARMACEUTICAL PRODUCTS</i>	175
MERIDIAN BIOSCIENCE	176
BUSINESS OVERVIEW	176
PRODUCTS	176
<i>TABLE 131 MERIDIAN BIOSCIENCE DIAGNOSTIC PRODUCTS</i>	176
NOVARTIS CORPORATION	177
BUSINESS OVERVIEW	177
PRODUCTS	178
<i>TABLE 132 NOVARTIS DIAGNOSTIC PRODUCTS</i>	178
<i>TABLE 133 NOVARTIS PHARMACEUTICAL PRODUCTS</i>	178
ORASURE TECHNOLOGIES INC.	178
BUSINESS OVERVIEW	178
PRODUCTS	179
<i>TABLE 134 ORASURE DIAGNOSTIC PRODUCTS</i>	179
ORTHO CLINICAL DIAGNOSTICS	179
BUSINESS OVERVIEW	179
PRODUCTS	179
<i>TABLE 135 ORTHO CLINICAL DIAGNOSTICS DIAGNOSTIC PRODUCTS</i>	179
PARATEK PHARMACEUTICALS	180
BUSINESS OVERVIEW	180
PFIZER INC	180
BUSINESS OVERVIEW	180
PRODUCTS	181
<i>TABLE 136 PFIZER VACCINE PRODUCTS</i>	181
<i>TABLE 137 PFIZER PHARMACEUTICAL PRODUCTS</i>	181
PRINCETON BIOMEDITECH CORPORATION	181
BUSINESS OVERVIEW	181
PRODUCTS	182
<i>TABLE 138 PRINCETON BIOMEDICTECH DIAGNOSTIC PRODUCTS</i>	182
PROTEIN SCIENCES CORPORATION	182
BUSINESS OVERVIEW	182
QUIDEL	183
BUSINESS OVERVIEW	183

TOPIC	PAGE NO.
PRODUCTS	183
<i>TABLE 139 QUIDEL DIAGNOSTIC PRODUCTS</i>	183
QUIGEN N.V.	183
BUSINESS OVERVIEW	184
PRODUCTS	184
<i>TABLE 140 QUIGEN DIAGNOSTIC PRODUCTS</i>	184
ROCHE LABORATORIES (HOFFMANN-LA ROCHE INC.)	184
BUSINESS OVERVIEW	184
PRODUCTS	185
<i>TABLE 141 ROCHE DIAGNOSTIC PRODUCTS</i>	185
<i>TABLE 142 ROCHE PHARMACEUTICAL PRODUCTS</i>	185
RIB-X PHARMACEUTICALS	185
BUSINESS OVERVIEW	185
ROMARK LABORATORIES	186
BUSINESS OVERVIEW	186
SANOFI PASTEUR	186
BUSINESS OVERVIEW	186
PRODUCTS	187
<i>TABLE 143 SANOFI PASTEUR PHARMACEUTICAL PRODUCTS</i>	187
SCICLONE PHARMACEUTICALS	187
BUSINESS OVERVIEW	187
PRODUCTS	188
<i>TABLE 144 SCICLONE PHARMACEUTICAL PRODUCTS</i>	188
SHANGHAI KEHUA BIO-ENGINEERING CO., LTD.	188
BUSINESS OVERVIEW	188
PRODUCTS	188
<i>TABLE 145 SHANGHAI KEHUA BIO-ENGINEERING DIAGNOSTIC PRODUCTS</i>	188
STANDARD DIAGNOSTICS INC	189
BUSINESS OVERVIEW	189
PRODUCTS	189
<i>TABLE 146 STANDARD DIAGNOSTICS DIAGNOSTIC PRODUCTS</i>	189
TETRAPHASE PHARMACEUTICALS	190
TRINITY BIOTECH PLC	190
BUSINESS OVERVIEW	190
PRODUCTS	191
<i>TABLE 147 TRINITY BIOTECH DIAGNOSTIC PRODUCTS</i>	191
VERTEX PHARMACEUTICALS	191
BUSINESS OVERVIEW	191
PRODUCTS	192
<i>TABLE 148 VERTEX PHARMACEUTICAL PRODUCTS</i>	192
VIIV HEALTHCARE	192
BUSINESS OVERVIEW	192
PRODUCTS	193
<i>TABLE 149 VIIV HEALTHCARE PHARMACEUTICAL PRODUCTS</i>	193

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE PROJECTED MARKET FOR INFECTIOUS DISEASES DIAGNOSTIC, VACCINE AND PHARMACEUTICAL PRODUCTS BY TYPE, THROUGH 2017 (\$ MILLIONS)	7
TABLE 1 GLOBAL PERCENTAGE OF DEATHS BY TYPE OF DISEASE, CAUSE, INCOME LEVEL (%)	11
TABLE 2 SELECTED MAJOR INFECTIOUS DISEASES, WORLDWIDE, 2011 (NUMBER OF CASES, TREATMENT OPTIONS)	11
TABLE 3 VACCINE-PREVENTABLE DISEASE DEATHS IN CHILDREN UNDER 5 YEARS OF AGE BY REGION, 2008 (000)	15
TABLE 4 PROJECTED GLOBAL MARKET FOR HUMAN INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS, THROUGH 2017 (\$ MILLIONS)	19
TABLE 5 PROJECTED GLOBAL MARKET FOR HUMAN INFECTIOUS DISEASE VACCINE PRODUCTS, THROUGH 2017 (\$ MILLIONS)	20
TABLE 6 PROJECTED GLOBAL MARKET FOR HUMAN INFECTIOUS DISEASE PHARMACEUTICAL PRODUCTS, THROUGH 2017 (\$ MILLIONS)	20
TABLE 7 PROJECTED GLOBAL MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC, VACCINE AND TREATMENT PRODUCTS, THROUGH 2017 (\$ MILLIONS)	21
TABLE 8 SELECTED MERGERS AND ACQUISITIONS, 2008-2013 (\$ MILLIONS)	24
TABLE 9 PROJECTED GLOBAL MARKET FOR INFECTIOUS DISEASE VACCINES, THROUGH 2017 (\$ MILLIONS)	26
TABLE 10 VIRUSES, THE DISEASES THEY CAUSE, AND AVAILABLE VACCINES	29
TABLE 11 BACTERIA, THE DISEASES THEY CAUSE, AND AVAILABLE VACCINES	30
TABLE 12 IMMUNIZATION SCHEDULE FOR CHILDREN FROM BIRTH TO 6 MONTHS	31
TABLE 13 IMMUNIZATION SCHEDULE FOR CHILDREN FROM 12 MONTHS TO 4 TO 6 YEARS	31
TABLE 14 IMMUNIZATION SCHEDULE FOR CHILDREN AND ADOLESCENTS FROM 7 TO 18	32
TABLE 15 TOP-SELLING INFECTIOUS DISEASE VACCINES WITH APPLICATION, MANUFACTURER AND REVENUE, 2011	35
TABLE 16 PROJECTED REGIONAL MARKETS FOR VACCINES, THROUGH 2017 (\$ MILLIONS)	35
TABLE 17 PROJECTED AMERICAS MARKET FOR INFECTIOUS DISEASE VACCINES BY REGION, THROUGH 2017 (\$ MILLIONS)	37
TABLE 18 PROJECTED AMERICAS MARKET FOR INFECTIOUS DISEASE VACCINES BY DISEASE, THROUGH 2017 (\$ MILLIONS)	38
TABLE 19 PROJECTED EMRA MARKET FOR HUMAN INFECTIOUS DISEASE VACCINES, BY REGION, THROUGH 2017 (\$ MILLIONS)	38
TABLE 20 PROJECTED EMRA MARKET FOR HUMAN INFECTIOUS DISEASE VACCINES, BY DISEASE, THROUGH 2017 (\$ MILLIONS)	39
TABLE 21 PROJECTED ASIAN MARKET FOR HUMAN INFECTIOUS DISEASE VACCINES, BY REGION, THROUGH 2017 (\$ MILLIONS)	39
TABLE 22 PROJECTED ASIAN MARKET FOR HUMAN INFECTIOUS DISEASE VACCINES, BY DISEASE, THROUGH 2017 (\$ MILLIONS)	40
TABLE 23 PROJECTED GLOBAL MARKET FOR VIRAL INFECTIOUS DISEASE DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2017 (\$ MILLIONS)	43
TABLE 24 PROJECTED GLOBAL MARKET FOR HEPATITIS DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2017 (\$ MILLIONS)	44
TABLE 25 PROJECTED GLOBAL MARKET FOR HSV DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2017 (\$ MILLIONS)	45
TABLE 26 CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF GENITAL HERPES BY BRAND NAME, TYPE AND MANUFACTURER, 2012	46

TABLE HEADING	PAGE NO.
TABLE 27 MEDICATIONS USED TO TREAT HSV BY BRAND NAME, GENERIC NAME AND MANUFACTURER	47
TABLE 28 PROJECTED GLOBAL MARKET FOR HEPATITIS B AND C DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2017 (\$ MILLIONS)	48
TABLE 29 HEPATITIS B AND C DIAGNOSTIC PRODUCT MARKET SHARE BY TYPE OF TEST AND REVENUES, 2011 (\$ MILLIONS/%)	48
TABLE 30 CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF HEPATITIS B AND C BY BRAND NAME AND MANUFACTURER, 2012	49
TABLE 31 HEPATITIS B AND C TREATMENT MANUFACTURER MARKET STANDING, BY REVENUES, 2011 (\$ MILLIONS)	51
TABLE 32 MEDICATIONS FOR THE TREATMENT OF HEPATITIS B AND C, 2012	52
TABLE 33 PROJECTED GLOBAL MARKET FOR HIV DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2017 (\$ MILLIONS)	53
TABLE 34 CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF HPV BY BRAND NAME, TYPE AND MANUFACTURER, 2012	57
TABLE 35 MEDICATIONS USED TO TREAT HPV BY BRAND NAME, GENERIC NAME, AND MANUFACTURER	57
TABLE 36 RSV DIAGNOSTIC PRODUCTS BY BRAND NAME, MANUFACTURER AND TYPE 2012	61
TABLE 37 PROJECTED GLOBAL MARKET FOR VIRAL INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS, THROUGH 2017 (\$ MILLIONS)	62
TABLE 38 PROJECTED GLOBAL MARKET FOR VIRAL INFECTIOUS DISEASE PHARMACEUTICAL PRODUCTS, THROUGH 2017 (\$ MILLIONS)	62
TABLE 39 PROJECTED GLOBAL MARKET FOR VIRAL INFECTIOUS DISEASE DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS BY REGION, THROUGH 2017 (\$ MILLIONS)	63
TABLE 40 PROJECTED MARKET FOR VIRAL DIAGNOSTIC PRODUCTS BY REGION, THROUGH 2017 (\$ MILLIONS)	64
TABLE 41 PROJECTED MARKET FOR VIRAL PHARMACEUTICAL PRODUCTS BY REGION, THROUGH 2017 (\$ MILLIONS)	65
TABLE 42 PROJECTED AMERICAS MARKET FOR VIRAL INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS BY REGION, THROUGH 2017 (\$ MILLIONS)	66
TABLE 43 PROJECTED AMERICAS MARKET FOR VIRAL INFECTIOUS DISEASE PHARMACEUTICAL PRODUCTS BY REGION, THROUGH 2017 (\$ MILLIONS)	67
TABLE 44 PROJECTED AMERICAS MARKET FOR VIRAL INFECTIOUS DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, BY DISEASE, THROUGH 2017 (\$ MILLIONS)	67
TABLE 45 PROJECTED EMRA MARKET FOR VIRAL INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS BY REGION, THROUGH 2017 (\$ MILLIONS)	68
TABLE 46 PROJECTED EMRA MARKET FOR VIRAL INFECTIOUS DISEASE PHARMACEUTICAL PRODUCTS BY REGION, THROUGH 2017 (\$ MILLIONS)	69
TABLE 47 PROJECTED EMRA MARKET FOR VIRAL INFECTIOUS DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, BY DISEASE, THROUGH 2017 (\$ MILLIONS)	70
TABLE 48 PROJECTED ASIAN MARKET FOR VIRAL INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS BY REGION, THROUGH 2017 (\$ MILLIONS)	71
TABLE 49 PROJECTED ASIAN MARKET FOR VIRAL INFECTIOUS DISEASE PHARMACEUTICAL PRODUCTS BY REGION, THROUGH 2017 (\$ MILLIONS)	71
TABLE 50 PROJECTED ASIAN MARKET FOR VIRAL INFECTIOUS DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, BY DISEASE, THROUGH 2017 (\$ MILLIONS)	72
TABLE 51 NEGLECTED TROPICAL BACTERIAL INFECTIOUS DISEASES	74
TABLE 52 PROJECTED GLOBAL MARKET FOR BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC AND TREATMENT PRODUCTS, THROUGH 2017 (\$ MILLIONS)	75

TABLE HEADING	PAGE NO.
TABLE 53 PROJECTED GLOBAL MARKET FOR BACTERIAL INFECTIOUS DISEASES DIAGNOSTICS, THROUGH 2017 (\$ MILLIONS)	75
TABLE 54 PROJECTED GLOBAL MARKET FOR BACTERIAL INFECTIOUS DISEASES PHARMACEUTICALS, THROUGH 2017 (\$ MILLIONS)	76
TABLE 55 PROJECTED GLOBAL MARKET FOR TB DIAGNOSTIC AND PHARMACEUTICAL TREATMENTS, THROUGH 2017 (\$ MILLIONS)	78
TABLE 56 PROJECTED MARKET FOR TB DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, BY REGION, THROUGH 2017 (\$ MILLIONS)	79
TABLE 57 HISTORY OF ANTIBIOTIC DISCOVERY AND APPROVAL	80
TABLE 58 ANTIBIOTIC CLASSES AND THEIR MODE OF ACTION	81
TABLE 59 ANTIBIOTICS APPROVED FOR USE IN FOOD-PRODUCING ANIMALS IN 2009, BY DRUG CLASS, POUNDS USED, AND PERCENTAGE OF TOTAL (POUNDS/%)	86
TABLE 60 ANTIBIOTIC-RESISTANT ORGANISMS AND DRUG CLASSES AFFECTED	87
TABLE 61 PROJECTED GLOBAL MARKET FOR BACTERIAL DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS BY REGION, THROUGH 2017 (\$ MILLIONS)	89
TABLE 62 PROJECTED AMERICAS MARKET FOR BACTERIAL DIAGNOSTIC AND PHARMACEUTICAL TREATMENTS, THROUGH 2017 (\$ MILLIONS)	91
TABLE 63 BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC PRODUCT MARKET IN THE AMERICAS BY REGION, THROUGH 2017 (\$ MILLIONS)	91
TABLE 64 BACTERIAL INFECTION PHARMACEUTICAL PRODUCT MARKET IN THE AMERICAS, BY REGION, THROUGH 2017 (\$ MILLIONS)	91
TABLE 65 PROJECTED AMERICAS MARKET FOR BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, BY DISEASE, THROUGH 2017 (\$ MILLIONS)	92
TABLE 66 PROJECTED EMRA MARKET FOR BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2017 (\$ MILLIONS)	93
TABLE 67 BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC PRODUCT MARKET IN EMRA BY REGION, THROUGH 2017 (\$ MILLIONS)	94
TABLE 68 BACTERIAL INFECTIOUS DISEASES PHARMACEUTICAL PRODUCT MARKET IN EMRA BY REGION, THROUGH 2017 (\$ MILLIONS)	94
TABLE 69 PROJECTED EMRA MARKET FOR BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS BY DISEASE, THROUGH 2017 (\$ MILLIONS)	94
TABLE 70 PROJECTED ASIA MARKET FOR BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC AND PHARMACEUTICAL TREATMENTS, THROUGH 2017 (\$ MILLIONS)	96
TABLE 71 BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC PRODUCT MARKET IN ASIA BY REGION, THROUGH 2017 (\$ MILLIONS)	96
TABLE 72 BACTERIAL INFECTIOUS DISEASES PHARMACEUTICAL PRODUCT MARKET IN ASIA, BY REGION, THROUGH 2017 (\$ MILLIONS)	97
TABLE 73 PROJECTED ASIAN MARKET FOR BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, BY DISEASE, THROUGH 2017 (\$ MILLIONS)	97
TABLE 74 NEGLECTED TROPICAL PARASITIC INFECTIOUS DISEASES	99
TABLE 75 ESTIMATED 2010 GLOBAL MALARIA CASES AND ESTIMATED DEATHS, RATE OF DECREASE OF MALARIA DEATHS SINCE 2000, BY REGION*	101
TABLE 76 PROJECTED GLOBAL MARKET FOR MALARIAL PREVENTION, DIAGNOSTIC AND PHARMACEUTICAL TREATMENTS, THROUGH 2017 (\$ MILLIONS)	102
TABLE 77 PROJECTED GLOBAL MARKET FOR INSECTICIDE-TREATED NETS, THROUGH 2017 (\$ MILLIONS)	102
TABLE 78 PROJECTED GLOBAL MARKET FOR MALARIAL DIAGNOSTIC PRODUCTS, THROUGH 2017 (\$ MILLIONS)	103

TABLE HEADING	PAGE NO.
TABLE 79 CURRENT PHARMACEUTICALS FOR TREATMENT OF MALARIA, WITH TREATMENT AND MANUFACTURER, 2012	104
TABLE 80 PROJECTED GLOBAL MARKET FOR MALARIAL DRUG TREATMENTS, THROUGH 2017 (\$ MILLIONS)	104
TABLE 81 PROJECTED GLOBAL MARKET FORMAL ARIAL PREVENTION, DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS BY REGION, THROUGH 2017 (\$ MILLIONS)	105
TABLE 82 PROJECTED AMERICAS MARKET FOR MALARIAL PREVENTION, DIAGNOSTIC AND PHARMACEUTICAL TREATMENTS, THROUGH 2017 (\$ MILLIONS)	107
TABLE 83 MALARIAL PREVENTION PRODUCT MARKET IN THE AMERICAS BY REGION, THROUGH 2017 (\$ MILLIONS)	107
TABLE 84 MALARIAL DIAGNOSTIC PRODUCT MARKET IN THE AMERICAS BY REGION, THROUGH 2017 (\$ MILLIONS)	108
TABLE 85 MALARIAL PHARMACEUTICAL PRODUCT MARKET IN THE AMERICAS BY REGION, THROUGH 2017 (\$ MILLIONS)	108
TABLE 86 PROJECTED EMRA MARKET FOR MALARIAL PREVENTIVE, DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2017 (\$ MILLIONS)	109
TABLE 87 MALARIAL PREVENTIVE PRODUCT MARKET IN EMRA, BY REGION, THROUGH 2017 (\$ MILLIONS)	109
TABLE 88 MALARIAL DIAGNOSTIC PRODUCT MARKET IN EMRA, BY REGION, THROUGH 2017 (\$ MILLIONS)	110
TABLE 89 MALARIAL PHARMACEUTICAL PRODUCT MARKET IN THE EMRA, BY REGION, THROUGH 2017 (\$ MILLIONS)	110
TABLE 90 PROJECTED ASIA MARKET FOR MALARIAL PREVENTION, DIAGNOSTIC, AND PHARMACEUTICAL TREATMENTS, THROUGH 2017 (\$ MILLIONS)	111
TABLE 91 MALARIAL PREVENTION PRODUCT MARKET IN ASIA BY REGION, THROUGH 2017 (\$ MILLIONS)	111
TABLE 92 MALARIAL DIAGNOSTIC PRODUCT MARKET IN ASIA BY REGION, THROUGH 2017 (\$ MILLIONS)	112
TABLE 93 MALARIAL PHARMACEUTICAL PRODUCT MARKET IN ASIA BY REGION, THROUGH 2017 (\$ MILLIONS)	112
TABLE 94 CURRENT ANT PARASITIC PHARMACEUTICALS WITH TRADENAME, GENERIC NAME, MANUFACTURER, AND AREA OF TREATMENT, 2012	113
TABLE 95 INFECTIOUS DISEASES PHARMACEUTICAL PRODUCT PIPELINE, BY DISEASE, 2012	120
TABLE 96 INFECTIOUS DISEASES PHARMACEUTICAL AND VACCINE PATENTS, BY PATENT NUMBER, DISEASE, COMPANY, PRODUCT DESCRIPTION AND APPROVAL DATE, FEBRUARY 2006 TO FEBRUARY 2013	129
TABLE 97 INFECTIOUS DISEASES DIAGNOSTIC PATENTS, BY PATENT NUMBER, DISEASE, COMPANY, PRODUCT DESCRIPTION, AND APPROVAL DATE, MARCH 2005-DECEMBER 2012	142
TABLE 98 INFECTIOUS DISEASES PHARMACEUTICAL, VACCINE, AND DIAGNOSTIC PRODUCT PATENTS BY COMPANY, MARCH 2005-FEBRUARY 2013	143
TABLE 99 INFECTIOUS DISEASE PRODUCT DIAGNOSIS, VACCINE AND TREATMENT PATENTS BY COUNTRY, JANUARY 2005 TO FEBRUARY 2013 (NUMBER/%)	145
TABLE 100 PATENTS ISSUED FOR DIAGNOSIS, VACCINE AND TREATMENT OF INFECTIOUS DISEASES, BY DISEASE, MARCH 2005-FEBRUARY 2013 (NUMBER/%)	146
TABLE 101 NUMBER OF INFECTIOUS DISEASES PATENTS FOR DIAGNOSTIC, VACCINE AND PHARMACEUTICAL PRODUCTS, BY DISEASE AND YEAR, 2005-2013	148
TABLE 102 ABBOTT PHARMACEUTICAL PRODUCTS	150
TABLE 103 ABBOTT DIAGNOSTIC PRODUCTS	151
TABLE 104 ALERE DIAGNOSTIC PRODUCTS	152
TABLE 105 ALFA SCIENTIFIC DESIGNS DIAGNOSTIC PRODUCTS	153

TABLE HEADING	PAGE NO.
TABLE 106 ATLAS LINK BIOTECH DIAGNOSTIC PRODUCTS	154
TABLE 107 ASTRA ZENECA PHARMACEUTICAL PRODUCTS	155
TABLE 108 BAXTER PHARMACEUTICAL PRODUCTS	156
TABLE 109 BAYER PHARMACEUTICAL PRODUCTS	156
TABLE 110 BECTON DICKINSON DIAGNOSTIC PRODUCTS	157
TABLE 111 BIORAD DIAGNOSTIC PRODUCTS	158
TABLE 112 BOEHRINGER INGELHEIM PHARMACEUTICAL PRODUCTS	159
TABLE 113 BRISTOL-MYERS SQUIBB PHARMACEUTICAL PRODUCTS	159
TABLE 114 CEPHEID DIAGNOSTIC PRODUCTS	160
TABLE 115 CRUCELL VACCINE PRODUCTS	161
TABLE 116 CUBIST PHARMACEUTICAL PRODUCT	162
TABLE 117 DIAGNOSTIC AUTOMATION/CORTEZ DIAGNOSTICS DIAGNOSTIC PRODUCTS	163
TABLE 118 DIAGNOSTIC PRODUCTS	164
TABLE 119 ENZO BIOCHEM DIAGNOSTIC PRODUCTS	165
TABLE 120 FIRST DIAGNOSTIC PRODUCTS	166
TABLE 121 GILEAD SCIENCES PHARMACEUTICAL PRODUCTS	167
TABLE 122 GLAXOSMITHKLINE PHARMACEUTICAL/VACCINE PRODUCTS	168
TABLE 123 HOLOGIC/GENPROBE DIAGNOSTIC PRODUCTS	169
TABLE 124 HOME ACCESS DIAGNOSTIC PRODUCTS	170
TABLE 125 IMMUNOSTICS DIAGNOSTIC PRODUCTS	171
TABLE 126 IND DIAGNOSTIC PRODUCTS	172
TABLE 127 JANSSEN THERAPEUTICS PHARMACEUTICAL PRODUCTS	173
TABLE 128 EDMIRA DIAGNOSTIC PRODUCTS	174
TABLE 129 MERCK VACCINE PRODUCTS	175
TABLE 130 MERCK PHARMACEUTICAL PRODUCTS	175
TABLE 131 MERIDIAN BIOSCIENCE DIAGNOSTIC PRODUCTS	176
TABLE 132 NOVARTIS DIAGNOSTIC PRODUCTS	178
TABLE 133 NOVARTIS PHARMACEUTICAL PRODUCTS	178
TABLE 134 ORASURE DIAGNOSTIC PRODUCTS	179
TABLE 135 ORTHO CLINICAL DIAGNOSTICS DIAGNOSTIC PRODUCTS	179
TABLE 136 PFIZER VACCINE PRODUCTS	181
TABLE 137 PFIZER PHARMACEUTICAL PRODUCTS	181
TABLE 138 PRINCETON BIOMEDICTECH DIAGNOSTIC PRODUCTS	182
TABLE 139 QUIDEL DIAGNOSTIC PRODUCTS	183
TABLE 140 QUIGEN DIAGNOSTIC PRODUCTS	184
TABLE 141 ROCHE DIAGNOSTIC PRODUCTS	185
TABLE 142 ROCHE PHARMACEUTICAL PRODUCTS	185
TABLE 143 SANOFI PASTEUR PHARMACEUTICAL PRODUCTS	187
TABLE 144 SCICLONE PHARMACEUTICAL PRODUCTS	188
TABLE 145 SHANGHAI KEHUA BIO-ENGINEERING DIAGNOSTIC PRODUCTS	188
TABLE 146 STANDARD DIAGNOSTICS DIAGNOSTIC PRODUCTS	189
TABLE 147 TRINITY BIOTECH DIAGNOSTIC PRODUCTS	191
TABLE 148 VERTEX PHARMACEUTICAL PRODUCTS	192
TABLE 149 VIIV HEALTHCARE PHARMACEUTICAL PRODUCTS	193

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE PERCENTAGE OF MARKET SHARE FOR INFECTIOUS DISEASE DIAGNOSTIC, VACCINE AND PHARMACEUTICAL PRODUCTS BY GEOGRAPHIC REGION, 2012 AND 2017 (%)	8
FIGURE 1 VACCINE-PREVENTABLE DEATHS IN CHILDREN UNDER FIVE YEARS OF AGE, 2008 (THOUSANDS)	14
FIGURE 2 VACCINE MANUFACTURING PROCESS	33
FIGURE 3 PERCENTAGE OF MARKET SHARE FOR VACCINES BY REGION, 2012 AND 2017	36
FIGURE 4 TOP PHARMACEUTICAL MANUFACTURERS IN THE HEPATITIS MARKET AND THEIR MARKET SHARE, 2011 (%)	51
FIGURE 5 PERCENTAGE OF THE GLOBAL VIRAL DIAGNOSTIC AND PHARMACEUTICAL MARKETS BY REGIONS, 2012 AND 2017 (%)	63
FIGURE 6 MARKET SHARE OF BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS BY REGION, 2012 AND 2017 (%)	89
FIGURE 7 GLOBAL MARKET FOR MALARIAL TREATMENTS BY REGION 2012 AND 2017 (%)	105
FIGURE 8 NUMBER OF INFECTIOUS DISEASES PRODUCT DIAGNOSIS, VACCINE AND TREATMENT PATENTS BY COUNTRY, JANUARY 2005-FEBRUARY 2013 (%)	146
FIGURE 9 INFECTIOUS DISEASES DIAGNOSTIC, VACCINE AND PHARMACEUTICAL PATENTS BY DISEASE ISSUED BETWEEN MARCH 2005 AND DECEMBER 2012, (%)	147